ScholarLens Back to search
2007•Journal watchRequires access

TNF Antagonists and Risk for Bacterial Infection

Allan S. Brett

Open publisher page 0 citations

Abstract

The tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab are used increasingly in rheumatoid arthritis (RA) and other

About this research paper

What this paper is about

The tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab are used increasingly in rheumatoid arthritis (RA) and other

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab are used increasingly in rheumatoid arthritis (RA) and other

Key concepts: Medicine, Tumor necrosis factor alpha, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
TNF Antagonists and Risk for Bacterial Infection — Research Paper | ScholarLens